EXCLUSIVE: Vivani Medical Tells Benzinga 'Clinical Development of Vivani's Exenatide Implant in Overweight and Obese Patients as Part of the Company's NPM-115 Program Remains on Track to Commence in the Fourth Quarter of 2024'
EXCLUSIVE: Vivani Medical Tells Benzinga 'Clinical Development of Vivani's Exenatide Implant in Overweight and Obese Patients as Part of the Company's NPM-115 Program Remains on Track to Commence in the Fourth Quarter of 2024'
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.